Allergan Aesthetics

What Allergan Aesthetics does

Allergan Aesthetics is the aesthetics subsidiary of AbbVie Inc. (NYSE: ABBV), formed after AbbVie's approximately $63 billion acquisition of Allergan plc in 2020. The company develops, manufactures, and markets a comprehensive portfolio of aesthetic medicine products including facial injectables (BOTOX Cosmetic, the JUVÉDERM Collection of six hyaluronic acid fillers, SKINVIVE HA microdroplet injectable, KYBELLA deoxycholic acid injection), body contouring technologies (CoolSculpting cryolipolysis, CoolTone magnetic muscle stimulation), breast implants and devices (Natrelle, KELLER FUNNEL 2, REVOLVE), professional skincare (SkinMedica, DiamondGlow, LATISSE), and regenerative medicine matrices (AlloDerm, Strattice, Artia). Allergan Aesthetics generated $4.860 billion in revenue, with BOTOX Cosmetic alone contributing $2.602 billion across four FDA-approved aesthetic indications (glabellar lines, lateral canthal lines, forehead lines, and platysma bands). Its pipeline includes Boey (trenibotulinumtoxinE), the first serotype E botulinum neurotoxin with rapid 8-hour onset and short 2-3 week duration, which received Health Canada approval and a positive CHMP opinion for 30 European countries in 2026.

The company operates a B2B2C go-to-market model, distributing exclusively through licensed healthcare providers (board-certified dermatologists, plastic surgeons, aesthetic physicians) and a U.S. med-spa channel of 10,500+ establishments. Provider enablement runs through the Allergan Medical Institute (AMI) training network (Austin, Orange County, Atlanta, plus Orlando partnership) and the Allergan Advantage provider portal with EDI-enabled ordering. Consumer-facing demand generation leverages brand websites, the Allē loyalty program, PatientFi custom financing (6.99%-25.99% APR, 12-72 month plans), medical conference presence, and content platforms (podcasts, Reddit AMAs, the Skin Quality Index). SKINVIVE has launched in 57 markets, the AA Signature multimodal treatment framework has launched in 25+ countries, and Allergan Aesthetics actively targets emerging consumer segments including the 52% of GLP-1 weight-loss patients expressing facial appearance concerns.

Customer segments are diversified across facial aesthetics consumers, body contouring patients, breast augmentation and reconstruction patients, skincare consumers, and healthcare provider accounts. Revenue is generated primarily through per-treatment product sales (one-time purchases of injectables, hardware sales of body contouring devices) priced at the provider level. Allergan Aesthetics holds no independent funding rounds as a wholly-owned subsidiary of AbbVie, with parent-company capital supporting R&D investment, regulatory pursuit (including a U.S. FDA Complete Response Letter for TrenibotE related to manufacturing, not safety/efficacy), and global commercial expansion across North America, Europe, Asia Pacific, and the Middle East.

Name

Allergan Aesthetics

Legal name

Allergan Aesthetics, an AbbVie company

Website

https://allerganaesthetics.com

Company type

Public

Founded year

2020

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Allergan Aesthetics is the aesthetics subsidiary of AbbVie (NYSE: ABBV), developing and commercializing a comprehensive portfolio of aesthetic medicine products — including BOTOX Cosmetic, JUVÉDERM fillers, SKINVIVE, CoolSculpting, and Natrelle breast implants — distributed through licensed healthcare providers and med spas globally, generating $4.860 billion in revenue.

Ownership category

akta.pro rank

Product category

Medical Aesthetics

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Cosmetics, Beauty Supplies, and Perfume Retailers (456120)

SIC

Perfumes, Cosmetics & Other Toilet Preparations (2844), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cosmetic Dermatology (Aesthetic Injectables) (HLAKACAE)

akta.pro secondary industries

Dermatology & Aesthetics Pharmaceuticals (HLAIAAAK), Professional/Backbar Skincare (Esthetician & Spa Use) (CRABAAAK), Skincare Devices (Cleansing Brushes, Microcurrent, LED, Dermaplaning) (CRABAKAI)

Keywords

• Medical aesthetics products
• Facial injectables neurotoxins
• Dermal fillers hyaluronic acid
• Body contouring technologies
• Breast implants reconstruction

Headquarters

HQ city

Irvine

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Neurotoxin Products: Revenue from BOTOX Cosmetic (onabotulinumtoxinA) and pipeline neurotoxin products including Boey (trenibotulinumtoxinE). BOTOX Cosmetic generated $2.602 billion. Includes multiple FDA-approved aesthetic indications for glabellar lines, lateral canthal lines, forehead lines, and platysma bands.
2. Dermal Fillers: JUVÉDERM Collection of Fillers including VOLUMA XC, VOLBELLA XC, VOLLURE XC, VOLUX XC, Ultra XC, Ultra Plus XC for cheek augmentation, lip augmentation, wrinkle correction, jawline definition, and temple hollowing treatment.
3. Body Contouring: CoolSculpting and CoolSculpting Elite fat-freezing treatments and CoolTone magnetic muscle stimulation devices for noninvasive body contouring targeting multiple body areas.
4. Breast Implants and Devices: Natrelle breast implants (silicone and saline), KELLER FUNNEL 2 delivery device, REVOLVE Advanced Adipose System for fat processing and transfer.
5. Skincare Products: SkinMedica professional skincare products, DiamondGlow dermabrasion devices and treatments, LATISSE eyelash growth treatment, regenerative medicine products (AlloDerm, Strattice, Artia tissue matrices).
6. Submental Contouring: KYBELLA (deoxycholic acid) injection for improvement of moderate to severe submental fat (double chin).
7. Allergan Aesthetics Total Revenue: Allergan Aesthetics generated $4.860 billion in total revenue as part of AbbVie. Strategic focus on platform expansion including neurotoxin portfolio, GLP-1 patient aesthetics market, and global market expansion.

Pricing tiers

Go-to-market motion4 records

Distribution channels5 records

Marketing channels10 records

Core offering

Allergan Aesthetics develops, manufactures, and markets a comprehensive portfolio of FDA-approved aesthetic medicine products distributed through licensed healthcare providers. Its core offerings include facial injectables (BOTOX Cosmetic neurotoxin, JUVÉDERM hyaluronic acid fillers, SKINVIVE hydrating microdroplet injectable, KYBELLA fat-reducing injection), noninvasive body contouring devices (CoolSculpting cryolipolysis, CoolTone magnetic muscle stimulation), Natrelle breast implants, SkinMedica skincare, LATISSE eyelash treatment, DiamondGlow dermabrasion, and regenerative medicine matrices.

Product overview

Allergan Aesthetics offers a comprehensive aesthetics portfolio spanning facial injectables (neurotoxins and dermal fillers), body contouring technologies, breast implants and reconstruction devices, professional skincare, and practice support services. The core portfolio includes BOTOX Cosmetic (neurotoxin), JUVÉDERM Collection of Fillers (hyaluronic acid fillers), SKINVIVE (hydrating HA injectable), KYBELLA (fat-reducing injection), CoolSculpting (cryolipolysis), and CoolTone (muscle stimulation). Supporting products include Natrelle breast implants, SkinMedica skincare, LATISSE eyelash treatment, DiamondGlow dermabrasion, and regenerative medicine matrices. Patient-facing services include Allē loyalty program and PatientFi financing, while provider support encompasses AMI training centers and Allergan Advantage platform.

Differentiator

Problem solved

Functional benefit

Products and services

• BOTOX Cosmetic (onabotulinumtoxinA) Prescription neurotoxin injection for temporary improvement of moderate to severe glabellar lines, lateral canthal lines, forehead lines, and platysma bands in adults. Administered by licensed healthcare providers.
• JUVÉDERM Collection of Fillers Six FDA-approved hyaluronic acid dermal fillers (VOLUMA XC, VOLBELLA XC, VOLLURE XC, VOLUX XC, Ultra XC, Ultra Plus XC) designed to treat 7 specific areas of the face including cheeks, lips, nasolabial folds, and jawline. Results last 1-2 years depending on product and area treated.
• SKINVIVE by JUVÉDERM First and only FDA-approved hyaluronic acid microdroplet injectable for improving cheek skin smoothness. Increases hydration to provide lasting glow for up to 6 months with optimal treatment. Launched in 57 global markets.
• KYBELLA (deoxycholic acid) injection Only FDA-approved injectable treatment that destroys fat cells to gradually improve the appearance and profile of moderate to severe submental fat (double chin) in adults.
• CoolSculpting FDA-cleared nonsurgical fat-freezing (cryolipolysis) technology that reduces pockets of fat in abdomen, flanks, under chin, and other areas with up to 20-25% fat layer reduction per single session.
• CoolTone Non-invasive body contouring treatment using Magnetic Muscle Stimulation (MMS) technology to strengthen, tone, and firm muscles of abdomen, buttocks, and thighs.
• Natrelle Breast Implants Breast implant collection offering smooth implants with five profile options and three unique gummy gels for breast augmentation and reconstruction in adults. #1 selected breast implant by U.S. physicians.
• KELLER FUNNEL 2 Device designed by a plastic surgeon to deliver breast implants with no-touch technique, reducing contamination risk during breast augmentation procedures.
• REVOLVE Advanced Adipose System Integrated system for high-quality fat processing designed for aspiration, harvesting, filtering, and transferring of autologous adipose tissue for aesthetic body contouring.
• SkinMedica Professional skincare line formulated with scientifically proven ingredients for skin rejuvenation, including age-defying and corrective products.
• LATISSE (bimatoprost ophthalmic solution) 0.03% First FDA-approved prescription treatment to grow eyelashes for people with inadequate lashes, clinically proven to deliver fuller, longer, and darker lashes at 16 weeks.
• DiamondGlow All-in-one clinically proven dermabrasion treatment using proprietary 3X1 technology to deliver immediate and long-lasting skin rejuvenation results.
• Regenerative Medicine (AlloDerm, Strattice, Artia) Portfolio of dermal matrix products including AlloDerm Select RTM, Strattice RTM, and Artia for plastic and general surgery applications including hernia repair and breast reconstruction.
• PatientFi Financing Custom patient financing solution offering low APR plans from 12-72 months, instant approval with no hard credit checks, and lower rates for Allergan Aesthetics patients.
• Allergan Medical Institute (AMI) Training arm of Allergan Aesthetics delivering hands-on trainings, roundtable forums, national symposia, live webcasts, and online learning for aesthetic providers across facial injectables, body contouring, skincare, and regenerative medicine.
• Boey (trenibotulinumtoxinE) First-in-class botulinum neurotoxin serotype E for temporary improvement of moderate to severe glabellar lines in adults. Features rapid onset within 8 hours and short duration of approximately 2-3 weeks.

Quantifiable outcome

• 74.8% of SKINVIVE participants achieved clinically significant improvement at one month for neck lines
• +8 more outcomes

Named customers5 records

Segments6 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature10 records

Partnerships

15 partnerships are on record, tiered minor, core and major.

• New BeautyminorGTM or Marketing Partner · 1 March 2026Partnership for Skin Quality Index educational resources including dedicated microsite and interactive quiz for consumers.
• PatientFicoreChannel Partner/ Reseller/ Distributor · 1 January 2026Custom financing solution for eligible Allergan Aesthetics patients offering lower APRs (6.99%-25.99%), 12-72 month payment plans, no hard credit checks, and 0.25% discount for Allergan patients.
• RedditminorGTM or Marketing Partner · 1 September 2025Marketing partnership leveraging Reddit's health communities for authentic discussions. Allergan Aesthetics among pharma brands engaging through Ask Me Anything sessions.
• Sisters Network Inc.minorGTM or Marketing Partner · 1 October 2024Breast reconstruction awareness partnership during Breast Cancer Awareness Month, supporting Black women navigating breast cancer journeys.
• Latina Association for Breast CancerminorGTM or Marketing Partner · 1 October 2024Breast reconstruction awareness partnership supporting Latina women facing breast cancer and postmastectomy reconstruction.
• Asian Women for HealthminorGTM or Marketing Partner · 1 October 2024Breast reconstruction awareness partnership supporting Asian women in breast cancer treatment and reconstruction decisions.
• Advanced Dermatology & Cosmetic SurgeryminorImplementation/ SI/ Consulting Partner · 1 March 2024Partnership to establish Allergan Aesthetics training center in Orlando, Florida for provider education and hands-on training.
• American Society of Plastic Surgeons (ASPS)coreStrategic or Co-development Partner · 1 January 2023LIMITLESS partnership supporting women plastic surgeons through storytelling and idea-sharing platform including docuseries, podcast, and Leaders' Summit.
• The Aesthetic SocietycoreStrategic or Co-development Partner · 1 January 2023LIMITLESS partnership and 'Beyond the Before & After' docuseries partnership showcasing real patient journeys of aesthetic plastic surgery.
• American Hernia SocietycoreStrategic or Co-development Partner · 1 January 2023LIMITLESS partnership supporting women plastic surgeons and development of current and future leaders in science, healthcare, and medicine.
• Hello AlicemajorGTM or Marketing Partner · 1 January 2023Online platform partnership for The Confidence Collective women entrepreneurs program, helping businesses launch and grow through skill-building, mentorship, and exclusive networking.
• Southern University and A&M College School of NursingminorGTM or Marketing Partner · 1 January 2023Educational partnership inspiring future nurse injectors about career pathways in aesthetic medicine, reaching 75+ nursing students.
• skinbetter sciencecoreStrategic or Co-development Partner · 1 January 2022Partnership for DREAM Initiative (Driving Racial Equity in Aesthetic Medicine), created in 2022 to address effects of systemic racism in aesthetic medicine. Includes Forces of Beauty report, Atlas, and CARE initiatives.
• Girls Inc.minorGTM or Marketing Partner · 1 January 2022Multi-year national partnership committed to creating opportunities for young women to explore and pursue STEM careers. Includes mentorship, campus visits, and panel discussions.
• Shutterstock StudiosminorGTM or Marketing Partner · 1 January 2022Partnership for DREAM Initiative imagery, creating thousands of royalty-free images showcasing beauty across race, culture, gender, age, and body type.

Scale indicators21 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Galderma: Global dermatology and aesthetics company with the closest competing portfolio: Restylane/Sculptra dermal fillers, Dysport neurotoxin, and skin-care lines. Direct head-to-head across fillers, neurotoxins and skincare makes Galderma Allergan's most relevant peer.
• Merz Aesthetics: Aesthetics subsidiary of Merz Pharma offering Xeomin (incobotulinumtoxinA) neurotoxin, Radiesse biostimulator, Belotero fillers and Ultherapy energy-based device. Competes directly with BOTOX/JUVÉDERM/CoolSculpting across injectables and devices.
• Revance Therapeutics: US aesthetics company behind Daxxify (daxibotulinumtoxinA), a long-duration neurotoxin challenging BOTOX Cosmetic, plus the RHA Collection of hyaluronic acid fillers competing with JUVÉDERM. Pure-play peer in core injectables.
• Evolus: Aesthetic medical technology company marketing Jeuveau (prabotulinumtoxinA), a botulinum toxin type A competing head-on with BOTOX Cosmetic in the US/Europe. Specialty pure-play in the neurotoxin segment.
• Hugel Inc. South Korean biopharmaceutical company with aesthetics botulinum toxins (Letybo/Botulax/Wellage) and HA fillers; recently hired former Allergan Aesthetics President Carrie Strom. Direct international competitor for both neurotoxins and fillers.
• BTL Industries: Private medical-device company behind EmSculpt (electromagnetic muscle stimulation), Emtone, and Exilis — direct competitors to CoolTone and adjacent to CoolSculpting in the non-invasive body-contouring device category.
• Cynosure Lutronic: Energy-based aesthetics device maker offering lasers, RF, and body-contouring platforms (e.g., TempSure) that compete with CoolSculpting/CoolTone and adjacent skincare/dermatology device sales channels used by Allergan Aesthetics providers.
• Solta Medical: Device-focused aesthetics brand (owned by Bausch Health) marketing Thermage RF skin-tightening, Fraxel lasers and Liposonix/truSculpt body-contouring systems. Competes for the same provider capital expenditure and consumer body-contouring demand as CoolSculpting/CoolTone.

Broad incumbents

• Ipsen: Global specialty pharma whose aesthetics neurotoxin Dysport competes directly with BOTOX Cosmetic; broader pharmaceutical portfolio makes it a broad incumbent comparison for Allergan Aesthetics' branded neurotoxin business.
• AbbVie: Allergan Aesthetics' parent company and a large pharma incumbent (NYSE: ABBV, $380B+ market cap) whose diversified immunology/oncology/aesthetics portfolio hosts this aesthetics segment. Useful as a structural peer for capital allocation and reporting comparisons, not a product competitor.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xinstagram.com/AllerganAesthetics
• LinkedInlinkedin.com/company/allergan-aesthetics
• Instagraminstagram.com/AllerganAesthetics

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Allergan Aesthetics